Congrats to FRENVEX for their study on azacitadine in #VEXAS led by Thibault Comont in @bloodjournal.bsky.social Confirmed inflammatory & hematologic responses in >50%. Molecular responses in >2/3rds! Toxicity common especially in first 3 cycles. ashpublications.org/blood/articl...
